Epirubicin
Metastatic Ureter Urothelial Carcinoma
Fred Hutchinson Cancer CenterPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Metastatic Ureter Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BB |
Pembrolizumab Fred Hutchinson Cancer Center | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 3 | B |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 3 | B |
Irinotecan National Cancer Institute (NCI) | Phase 3 | B |
Atezolizumab Alliance for Clinical Trials in Oncology | Phase 3 | B |
Lifileucel Roswell Park Cancer Institute | Phase 2 | CCC |
Fludarabine Roswell Park Cancer Institute | Phase 2 | CCC |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →